Search results
Results from the WOW.Com Content Network
September 27, 2024 at 9:39 AM. (Reuters) -The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a chronic lung disease, commonly ...
Dupilumab. Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. [6][7][8][4] It is also used for the treatment of eosinophilic esophagitis [9] and prurigo nodularis.
94558-4, 95209-3, 96119-3, 97097-0. COVID-19 rapid antigen tests or RAT s, also frequently called COVID-19 lateral flow tests or LFT s, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5 ...
In unvaccinated high-risk people with COVID‑19, nirmatrelvir/ritonavir can reduce the risk of hospitalization or death by 88% if taken within five days of symptom onset. [19] People who take nirmatrelvir/ritonavir also test negative for COVID‑19 about two and a half days earlier than people who do not. [20]
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
Flowflex COVID-19 Antigen Home Test, 1 Pack, 5 Tests Total. FlowFlex COVID-19 Antigen Home Test $31.99 at Amazon. FlowFlex COVID-19 Antigen Home Test $42.99 at Target. FlowFlex’s home testing ...
The development of COVID-19 tests was a major public health priority during the early months of the COVID-19 pandemic. In January 2020, scientists from China published the first genetic sequences of SARS-CoV-2 via virological.org , [ 3 ] a "hub for prepublication data designed to assist with public health activities and research". [ 4 ]
The biotech's current biggest growth driver, though, is Dupixent, a medicine for eczema. Regeneron co-markets Dupixent with Sanofi. The drug's global sales in the first quarter (recorded by Sanofi ...